Should Pro Medicus’ 7-Year, Usage-Based St. Luke’s Deal Require Action From ASX:PME Investors?

Simply Wall St.

Aug 14

In August 2026, Pro Medicus announced it had secured a 7-year, A$23,000,000 contract with St. Luke’s Health System to deploy its cloud-based Visage 7 enterprise imaging platform across three US states...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2659429961"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2659429961\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2659429961?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574","is_english":true,"pubTime":"2026-08-14 19:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2659429961","market":"nz","top_or_hot":-1,"title":"Should Pro Medicus’ 7-Year, Usage-Based St. Luke’s Deal Require Action From ASX:PME Investors?","media":"Simply Wall St.","content":"<div>\n<p>In August 2026, Pro Medicus announced it had secured a 7-year, A$23,000,000 contract with St. Luke’s Health System to deploy its cloud-based Visage 7 enterprise imaging platform across three US states...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-pme/pro-medicus-shares/news/should-pro-medicus-7-year-usage-based-st-lukes-deal-require\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should Pro Medicus’ 7-Year, Usage-Based St. Luke’s Deal Require Action From ASX:PME Investors?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould Pro Medicus’ 7-Year, Usage-Based St. Luke’s Deal Require Action From ASX:PME Investors?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-14 19:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/healthcare/asx-pme/pro-medicus-shares/news/should-pro-medicus-7-year-usage-based-st-lukes-deal-require><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In August 2026, Pro Medicus announced it had secured a 7-year, A$23,000,000 contract with St. Luke’s Health System to deploy its cloud-based Visage 7 enterprise imaging platform across three US states...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-pme/pro-medicus-shares/news/should-pro-medicus-7-year-usage-based-st-lukes-deal-require\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PME.AU","symbol_name":"PRO MEDICUS LTD","start_time":0,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-pme/pro-medicus-shares/news/should-pro-medicus-7-year-usage-based-st-lukes-deal-require","article_id":"2659429961","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-pme/pro-medicus-shares/news/should-pro-medicus-7-year-usage-based-st-lukes-deal-require","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2659429961","pubTimestamp":1786706591,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In August 2026, Pro Medicus announced it had secured a 7-year, A$23,000,000 contract with St. Luke’s Health System to deploy its cloud-based Visage 7 enterprise imaging platform across three US states, covering both Visage 7 Viewer and Visage 7 Workflow.\nAn interesting element of this deal is its transaction-based licensing model, which ties Pro Medicus’s revenue to actual imaging usage and creates scope for scalable income over the contract term.\nWe’ll now explore how this long-term,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"PME.AU":"PRO MEDICUS LTD","BK7094":"医疗保健技术","BK4211":"区域性银行","ISBC":"投资者银行"},"translate_title":"Pro Medicus 与 St. Luke 达成的为期 7 年、基于使用量的交易是否需要 ASX:PME 投资者采取行动？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ISBC":1.5,"PME.AU":1.5},"content_text":"In August 2026, Pro Medicus announced it had secured a 7-year, A$23,000,000 contract with St. Luke’s Health System to deploy its cloud-based Visage 7 enterprise imaging platform across three US states, covering both Visage 7 Viewer and Visage 7 Workflow. An interesting element of this deal is its transaction-based licensing model, which ties Pro Medicus’s revenue to actual imaging usage and creates scope for scalable income over the contract term. We’ll now explore how this long-term, usage-based St. Luke’s contract could influence Pro Medicus’s existing investment narrative built around US hospital growth. AI is about to change healthcare. These 7 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.AdvertisementPro Medicus Investment Narrative RecapTo own Pro Medicus, you need to believe its premium imaging platform can keep winning large US health systems on long contracts that translate into growing transaction revenue. The St. Luke’s A$23,000,000, 7 year deal reinforces that US hospital thesis but does not materially change the near term risk that any slowdown in US imaging volumes or tighter hospital budgets could pressure pricing and premium multiples. Against this backdrop, the February 2026 half year result, with revenue of A$128.94 million and net income of A$171.22 million, is the most relevant recent announcement. It reminded investors that expectations for growth and margins are already very high, so new contracts like St. Luke’s are being assessed not just on size, but on how reliably they may convert the existing backlog into future earnings. However, investors should also be aware that if US imaging budgets tighten or buyers prioritise cheaper alternatives... Read the full narrative on Pro Medicus (it's free!)Pro Medicus' narrative projects A$453.7 million revenue and A$259.5 million earnings by 2029. This requires 23.5% yearly revenue growth and an A$24.8 million earnings increase from A$234.7 million today.Uncover how Pro Medicus' forecasts yield a A$190.74 fair value, a 7% upside to its current price.Exploring Other PerspectivesASX:PME 1-Year Stock Price Chart Some of the lowest ranked analysts were already cautious, assuming earnings of about A$223.7 million by 2029 and lower margins, so a contract like St. Luke’s might eventually push those more pessimistic views to adjust, but it also highlights how differently you and other investors can interpret the same A$400.9 million revenue path.Explore 10 other fair value estimates on Pro Medicus - why the stock might be worth as much as 12% more than the current price!The Verdict Is YoursDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Pro Medicus research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.Our free Pro Medicus research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pro Medicus' overall financial health at a glance.Seeking Other Investments?Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.The latest GPUs need a type of rare earth metal called Dysprosium and there are only 28 companies in the world exploring or producing it. Find the list for free.Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}